
Clinical Trial Delays: Key Challenges from Phase I to III
Learn why over 85% of clinical trials face delays. Updated for 2026, this analysis covers key scientific, operational, and regulatory challenges from Phase I to III, including site activation bottlenecks, AI-driven recruitment, and ICH E6(R3) GCP updates.
